The PKD Therapeutics Market is Forecast to Grow Until 2019

Tuesday 13 March 2012, Amsterdam

The industry analysis specialist, has released its new report, “Polycystic Kidney Disease (PKD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Polycystic kidney disease Therapeutics market. The report identifies the key trends shaping and driving the global Polycystic kidney disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Polycystic kidney disease Therapeutics sector.


The PKD Therapeutics Market is Forecast to Grow Until 2019

The global PKD therapeutics market was worth $111.4m in 2006, and grew at a Compound Annual Growth Rate (CAGR) of 1.7% to reach $121.0m in 2011. The market is forecast to grow at a CAGR of 16.1% over the next eight years to reach $400.2m by 2019. This growth is primarily attributed to the expected launch of Samsca (tolvaptan) for the treatment of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). The scheduled patent expiries of Cozaar (US and Europe), Aceon (US), Coreg (US) and Diovan (Europe) are expected to have a minimal impact on the PKD therapeutics market as the annual cost of therapy associated with these drugs is significantly low.


Unmet Need Expected to Decline in the Near Future

They has found that the PKD therapeutics market has significant unmet need due to the absence of approved drug therapies. The currently prescribed drugs are primarily used to alleviate symptoms and delay the disease progression. Although the treatment of PKD still lacks disease modifying therapies, usage of the antihypertensive medications have yielded moderate therapeutic outcomes. The unmet need in terms of efficacy in this market is significant since none of the currently used therapy options are effective in retarding or halting the progression of PKD. The approval of pipeline products in the near future is likely to address some of the unmet needs in the PKD therapeutics market. The clinical unmet need is therefore likely to decline in the near future.


Strong Clinical Pipeline with First-in-Class Molecules

An analysis shows that the PKD developmental pipeline is strong with eight molecules in various stages of clinical development. The pipeline is filled with various novel therapeutic drug classes, which include mTOR inhibitors, a vasopressin V2-receptor antagonist, a somatostatin receptor (SSTR) agonist and Src inhibitor. There are four first-in-class molecules in Phase III and the expected launch of these molecules in the near future is expected to address the current unmet needs. A strong clinical pipeline, coupled with high unmet need in the PKD therapeutics market, is expected to propel the market with a high growth rate during the forecast period.